Loading the security page…
A security analysis is not yet prepared for this market.
Based on the fiscal year ended 31 December 2025
The sector median covers every company in the sector on the US market, loss-making ones included.
Drugs Made In America Acquisition Corp. (DMAA) is a company in the Financials sector; its shares trade on Nasdaq.
The price of Drugs Made In America Acquisition Corp. (DMAA) on November 11, 2026 is 10.90 $, 0.00 % on the day. Over the past year the price changed by +5.59 %. The P/E ratio is 19.66, which is above the sector median (13.01). Market capitalization is 116.82 million $, rank 101 among 203 stocks of the same industry with a known capitalization.
Drugs Made In America Acquisition Corp. trades on Nasdaq under the ticker DMAA. The company belongs to the Financials sector. The trading history on this page starts on 25 February 2025.
Over the past 52 weeks DMAA has traded between 10.31 $ and 10.91 $. As of 11 November 2026 the price stood 98.33% of the way from the 52-week low to the high.
Over one year DMAA shares rose 5.59%; over six months they rose 2.74%. Volatility over 90 days is 1.69%. Dividends are not included: this is price change only, as of 11 November 2026.
DMAA trades at a price-to-earnings ratio of 19.7, above the sector median of 13.0. Calculated from reports for the period ending 31 December 2025.